A Look Back at Surgical Equipment & Consumables - Specialty Stocks' Q4 Earnings: Intuitive Surgical (NASDAQ:ISRG) Vs The Rest Of The Pack

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the surgical equipment & consumables - specialty stocks, including Intuitive Surgical (NASDAQ:ISRG) and its peers.

The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly.

The 4 surgical equipment & consumables - specialty stocks we track reported a satisfactory Q4. As a group, revenues missed analysts’ consensus estimates by 8.5% while next quarter’s revenue guidance was in line.

In light of this news, share prices of the companies have held steady as they are up 4.8% on average since the latest earnings results.

Intuitive Surgical (NASDAQ:ISRG)

Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties.

Intuitive Surgical reported revenues of $2.87 billion, up 18.8% year on year. This print exceeded analysts’ expectations by 1%. Overall, it was an exceptional quarter for the company with an impressive beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.

Intuitive Surgical scored the fastest revenue growth of the whole group. Investor expectations, however, were likely higher than Wall Street’s published projections, leaving some wishing for even better results (analysts’ consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 4.6% since reporting and currently trades at $501.86.

We think Intuitive Surgical is a good business, but is it a buy today? Read our full report here, it’s free.

Best Q4: LeMaitre (NASDAQ:LMAT)

Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions.

LeMaitre reported revenues of $64.45 million, up 15.7% year on year, outperforming analysts’ expectations by 2.4%. The business had an exceptional quarter with a solid beat of analysts’ EPS guidance for next quarter estimates and a solid beat of analysts’ full-year EPS guidance estimates.

LeMaitre delivered the biggest analyst estimates beat among its peers. The market seems happy with the results as the stock is up 17.9% since reporting. It currently trades at $108.20.

Is now the time to buy LeMaitre? Access our full analysis of the earnings results here, it’s free.

Slowest Q4: Teleflex (NYSE:TFX)

With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE:TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide.

Teleflex reported revenues of $569 million, down 28.5% year on year, falling short of analysts’ expectations by 38.3%. It was a disappointing quarter as it posted a significant miss of analysts’ full-year EPS guidance estimates and a significant miss of analysts’ revenue estimates.

Teleflex delivered the weakest performance against analyst estimates and slowest revenue growth in the group. Interestingly, the stock is up 9% since the results and currently trades at $121.96.

Read our full analysis of Teleflex’s results here.

Integra LifeSciences (NASDAQ:IART)

Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.

Integra LifeSciences reported revenues of $434.9 million, down 1.7% year on year. This number beat analysts’ expectations by 1%. Zooming out, it was a mixed quarter as it also recorded a solid beat of analysts’ organic revenue estimates but revenue guidance for next quarter missing analysts’ expectations significantly.

Integra LifeSciences scored the highest full-year guidance raise among its peers. The stock is down 3.1% since reporting and currently trades at $11.24.

Read our full, actionable report on Integra LifeSciences here, it’s free.

Want to invest in winners with rock-solid fundamentals? Check out our Strong Momentum Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.